FORMULATION OF SOLID DOSAGE FORM CONTAINING CLOPIDOGREL AND CILOSTAZOL AND ITS HPLC ANALYSIS
DOI:
https://doi.org/10.22159/ijpps.2017v9i6.13987Keywords:
Cilostazol, Clopidogrel, HPLC, ValidationAbstract
Objective: The verify now P2Y12 assay suggested that addition of cilostazol to clopidogrel proves to be efficious in the treatment of patients with cardiovascular disease (CVD). Based on these findings, an attempt has been made to formulate solid dosage form containing the two drugs at the recommended concentrations and develop and validate reverse phase high-performance liquid chromatography (HPLC) method for their simultaneous estimation.
Methods: A combined tablet dosage form containing cilostazol (100 mg) and clopidogrel (75 mg) was formulated by direct compression method. A reverse phase HPLC method using C8 column, employing 0.025M phosphate buffer: methanol: acetonitrile (20:40:40% v/v) as mobile phase at a flow rate of 1 ml/min with ultraviolet (UV) detection at 237 nm was developed and validated as per International Council on Harmonisation (ICH) guidelines.
Results: The prepared powder blend showed excellent flow properties and formulated tablet passed the standard tests for tablets. The tablets were suitably analyzed by the reverse phase HPLC method with a retention time (RT) of 3.82 and 7.72 min for cilostazol and clopidogrel respectively. The method exhibited linearity (10-100mg/ml for cilostazol and 7.5-75mg/ml for clopidogrel) with r2= 0.999 for both drugs respectively. The recoveries of cilostazol and clopidogrel were 98.97% and 98.94% respectively. The relative standard deviation (RSD) was<2% indicating good method precision. The stability indicating properties evaluated by forced degradation studies showed good separation of the drugs from their degradation products.
Conclusion: A simple, precise, robust, stability-indicating HPLC method was developed for simultaneous assay of cilostazol and clopidogrel in prepared tablet formulation and validated as per ICH guidelines. This method can be employed for the analysis and stability studies of solid dosage forms containing the two drugs.
Downloads
References
Indian Pharmacopoeia, Government of India, Ministry of Health and Welfare, New Delhi; 2014.
British National Formulary. 68th ed. British Medical Association and Royal Pharmaceutical Society of Great Britain, London, September; 2014.
United State Pharmacopoeia. Asian ed. Rockville; 2013.
Maruyama H, Lakeda H, Dembo T, Nayoga H, Kato Y, Fukuoka T. Clopidogrel resistance and the effect of combination cilostazol in patients with ischemic stroke or carotid artery stenting using the verify now P2Y12 assay. Intern Med 2011;50:695-8.
Basniwal PK, Shrivastava PK, Jain D. Hydrolytic degradation profile and RP-HPLC estimation of cilostazol in tablet dosage form. Indian J Pharm Sci 2008;70:222.
Dharmendra D, Karan M, Bhoomi P, Rajshree CM. Quantification of cilostazol and telmisartan in combination using risk profile and uncertainty contour: a contemporary validation approach. J Chromatogr Sep-Tech 2015;6:1-8.
Sultana N, Ali KA, Arayne MS, Nawaz M. Simultaneous determination of clopidogrel and aspirin by RP-HPLC from bulk material and dosage formulations using multivariate calibration technique. J Chromatogr Sci 2011;49:165-9.
Kurien J, Jayasehar P. Stability indicating HPLC determination of Clopidogrel bisulfate in pharmaceutical dosage forms. Pharmacie Globale: Int J Chem Pharm 2013;4:1-5.
Dimple B, Vinodh M, Vinayak M. Development and validation of RP-HPLC method for the estimation of clopidogrel bisulphate. Malaysian J Anal Sci 2013;17:387-93.
Mounika A, Sriram N. Method development and validation of clopidogrel bisulphate by reverse phase-HPLC in bulk and pharmaceutical dosage forms. Int J Pharm Anal Res 2012;1:1-7.
Mashelkar UC, Renapurkar SD. A LC-MS compatible stability-indicating HPLC assay method for Cefdinir. Int J Chem Tech Res 2010;2:114-21.
Bramer SL, Tata PN, Vengurlekar SS, Brisson JH. Method for the quantitative analysis of cilostazol and its metabolites in human plasma using LC/MS/MS. J Pharm Biomed Anal 2001;26:637-50.
Wang J, Wang Z, Chen C, Wang Z, Liu N, Ma J, et al. Gradient elution LC-ESI-MS determination of cilostazol in rat plasma and its application. Latt Am J Pharm 2012;31:240-4.
Sivarama KV, Ravi KD, Balamuralikrishna K, Rambabu C. Development and validation of a stability-indicating RP-HPLC method for the determination of clopidogrel bisulphate in bulk and its dosage form. Pharm Chem 2014;6:366-74.
Reddy DP, Swarnalatha D, Sidda RB, Karthik SKP, Sardar UM. Design, development and characterization of the clopidogrel bisulfate transdermal drug delivery system. Asian J Pharm Clin Res 2015;8:277-80.
Singh S, Choudhary N, Rai J, Siddiqui I, Sharma S. A validated RP-UPLC method development for simultaneous estimation of lansoprazole and naproxen in bulk and tablet dosage form. Asian J Pharm Clin Res 2013;6:150-2.
Nagavi BJ, Gurupadayya B. Simultaneous estimation of clopidogrel and atorvastatin in human plasma using bio-analytical RP-Ultra fast liquid chromatographic method. Int J Chem Pharm Res 2015;7:30-5.
Gurupadayya BM, Nagavi JB. RP-UFLC method development and validation for simultaneous estimation of clopidogrel, pantoprazole, and rosuvastatin in human plasma: drug interaction studies. Int J Pharm Pharm Sci 2014;6:490-6.
Validation of analytical procedures, text, and methodology, ICH Harmonized Guidelines, Q2 (R1), Geneva; 2005. p. 1-13.
Text on Validation of Analytical Procedures. ICH, Harmonized Guidelines, Q2A, Geneva; 1994. p. 1-5.
Validation of Analytical Procedures: Methodology. ICH, Harmonized Guidelines, Q2B, Geneva; 1996. p. 1-8.
Kurien J, Jayasekhar P. Stability indicating HPLC determination of cilostazol in pharmaceutical dosage forms. Int J Pharm Bio Sci 2014;5:176-86.
Antic D, Filipi S, Agbaba D. A simple and sensitive TLC method for determination of clopidogrel and its impurity SR 26334 in pharmaceutical products. Acta Chromatogr 2007;18:199-206.
Housheh S, Trefi S, Haroun M, Chehna MF. A novel GC/MS, FTIR and NMR for the identification and characterization of clopidogrel bisulphate degradation products. Indian J Pharm Educ Res 2015;49:240-50.
Published
How to Cite
Issue
Section
